Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Peripheral Blood Collection for Immune Profiling.
- Кому может быть актуально
- Состояния в реестре: Lung Cancer (Diagnosis), Sarcoidosis, Chronic Obstructive Pulmonary Disease, Immunotherapy Resistance. Базовые параметры: до 80 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Бельгия
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD). The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation. Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment. The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.
Вмешательства
- Другое Peripheral Blood Collection for Immune Profiling
Participants provide biological samples for immune profiling and translational research. Samples include peripheral blood and, when available from routine clinical care, additional specimens such as tumor tissue or rlymph node, bone marrow. No experimental treatments are given. Collected samples are analyzed to characterize immune cell populations and their functional and molecular features, with the aim of studying immune mechanisms involved in lung cancer, sarcoidosis, and COPD, as well as fac
Первичные конечные точки
- Progression free survival [Срок оценки: Throughout the entire study, approximately during 7 years]
Критерии участия
Критерии включения
- Diagnosis of lung cancer
- Presence of precancerous lung lesions
- Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \[COPD\]) prior to any treatment
- Control group: individuals without known lung disease
- Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD)
- Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected
Критерии исключения
- Systemic corticosteroid therapy > 10 mg/day prednisone (or equivalent)
- Acute infection at the time of inclusion
- Refusal or inability to provide informed consent (or assent, when applicable)
- Chronic inflammatory lung disease currently treated with immunosuppressive therapy
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Да
Дизайн исследования
- Распределение
- Нерандомизированное
- Модель
- Параллельные группы
- Маскирование
- Открытое
- Основная цель
- Фундаментальное исследование
Центры проведения
Бельгия · 1 центр
- Cliniques universitaires saint Luc — Brussels
Публикации
- Desai A, Prasad V. Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions? J Gen Intern Med. 2021 Oct;36(10):3202-3204. doi: 10.1007/s11606-021-06806-5. Epub 2021 Apr 26. No abstract available. PMID 33904047
- Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535. PMID 31050774
- Delhez N, Aboubakar Nana F, Houbion C, Bayard A, Bruger A, Vanhaver C, Brandau S, van der Bruggen P, Hirsch T. Deciphering neutrophil heterogeneity in human blood and tumors: Methods for isolating neutrophils and assessing their effect on T-cell proliferation. Methods Cell Biol. 2025;191:151-196. doi: 10.1016/bs.mcb.2024.10.010. Epub 2024 Nov 25. PMID 39824555
- Bruger AM, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T, Santibanez J, Saraiva M, Van Ginderachter JA, Brandau S. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother. 2019 Apr;68(4):631-644. doi: 10.1007/s00262-018-2170-8. Epub 2018 May 21. PMID 29785656
- Vanhaver C, Aboubakar Nana F, Delhez N, Luyckx M, Hirsch T, Bayard A, Houbion C, Dauguet N, Brochier A, van der Bruggen P, Bruger AM. Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype. Life Sci Alliance. 2023 Nov 6;7(1):e202302332. doi: 10.26508/lsa.202302332. Print 2024 Jan. PMID 37931958
Идентификаторы
NCT: NCT07384897 · IMMUNOPOUMON2